Home / Stocks / Krebs Biochemicals & Ind
KREBSBIO

Krebs Biochemicals & Ind Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹57.15

Change

-1.84 (-3.12%)

Open

₹60.0

Prev. Close

₹58.99

Day High

₹60.1

Day Low

₹56.75

Volume Analysis

Traded

15,595

Delivered

12,772

Delivery %

81.9%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (2)

  • •Below-average fundamentals quality score (44/100)
  • •Low operating margin (-23.0%)

Opportunities (0)

No signal for this stock

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹62.6 ₹61.35 ₹59.25 ₹58.0 ₹55.9 ₹54.65 ₹52.55
Fibonacci ₹61.35 ₹60.07 ₹59.28 ₹58.0 ₹56.72 ₹55.93 ₹54.65
Camarilla ₹58.07 ₹57.76 ₹57.46 ₹58.0 ₹56.84 ₹56.54 ₹56.23

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-18.26%

1 Week

-2.74%

1 Month

+1.94%

3 Months

+6.6%

6 Months

-2.92%

1 Year

-15.12%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

0.0%

Net margin -70.83% × asset turnover 0.0x × equity multiplier -0.94x

Company Overview

Sector

Healthcare

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Krebs Biochemicals & Ind scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 44/100. The strongest factor is Financial Strength (100/100), while Growth (0/100) is the weakest area to weigh before deciding. Notably: Below-average fundamentals quality score (44/100); low operating margin (-23.0%).

TopFund Score — Fundamentals Quality

44/100 — Weak

Data confidence: 68/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

0

Cash Flow

50

Corporate Governance

56

Institutional Ownership

31

Business Quality

33

Risk & Volatility

33

Liquidity

50

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Company has enclosed herewith copy of newspaper advertiement for financial results for the quarter ended 30.09.2026

Submitted Regulation 74(5) certificate for quarter ended September 30, 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 (S) Dec 2023 (S) Mar 2024 (S) Jun 2024 (S) Sep 2024 (S) Dec 2024 (S) Mar 2025 (S) Jun 2025 (S) Sep 2025 (S) Dec 2025 (S) Mar 2026 (S) Jun 2026 (S) Sep 2026 (S)
Sales + 15 13 12 13 13 11 6 5 4 7 7 7 6
Expenses + 16 15 15 15 16 16 12 8 7 7 8 6 8
Operating Profit -1 -2 -3 -2 -3 -5 -5 -2 -3 0 -1 1 -2
OPM % -6.04% -16.1% -26.07% -16.99% -21.15% -41.06% -88.69% -38.14% -67.15% 4.13% -12.63% 11.75% -33.33%
Other Income + 0 0 0 0 0 0 0 0 0 0 2 0 0
Interest 1 1 1 1 1 2 2 2 2 2 2 2 2
Depreciation 2 2 2 2 2 2 2 2 2 2 2 2 2
Profit before tax -4 -5 -6 -5 -6 -8 -8 -5 -6 -3 -2 -2 -5
Tax % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.24% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Net Profit + -4 -5 -6 -5 -6 -8 -8 -5 -6 -3 -2 -2 -5
EPS in Rs -2 -2 -3 -2 -3 -4 -4 -2 -3 -1 -1 -1 -3
Raw PDF — — — — — — — — — — — — —
YoY Sales growth -29 43 4 22 -14 -12 -49 -57 -68 -37 12 27 39

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 (S) 6m Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S)
Sales + 0 1 3 34 48 33 54 60 52 50 43 24
Expenses + 5 14 11 41 58 52 71 94 68 59 58 29
Operating Profit -5 -12 -8 -8 -10 -19 -18 -34 -16 -9 -15 -5
OPM % — -1,088.0% -248.0% -22.0% -20.0% -56.0% -33.0% -57.0% -30.0% -17.0% -35.0% -23.0%
Other Income + 3 1 0 -1 0 0 1 1 1 0 1 2
Interest 4 1 3 5 6 6 6 5 3 5 6 7
Depreciation 2 4 4 4 4 5 5 6 7 7 7 6
Profit before tax -8 -16 -16 -18 -20 -29 -28 -45 -25 -20 -27 -17
Tax % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Net Profit + -8 -16 -16 -18 -20 -29 -28 -45 -25 -20 -27 -17
EPS in Rs -8 -12 -11 -12 -12 -16 -14 -21 -11 -9 -13 -8
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Sales growth — — 183 946 41 -30 61 11 -13 -3 -14 -45

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S) Sep 2026 (S)
Reserves 9 0 -12 -32 -31 -43 -62 -97 -121 -141 -168 -184 -192
Borrowings + 61 31 48 56 53 66 111 143 183 194 212 225 227
Other Liabilities + 29 73 73 87 103 93 91 122 91 104 103 101 102
Total Liabilities 108 116 122 126 142 134 159 190 175 178 169 163 159
Fixed Assets + 58 93 102 101 101 105 118 139 147 150 146 142 139
CWIP 0 11 4 4 3 4 12 8 4 2 3 2 2
Investments 0 0 0 0 0 0 0 0 0 0 0 0 0
Other Assets + 50 13 16 21 38 24 29 43 24 26 20 20 18
Total Assets 108 116 122 126 142 134 159 190 175 178 169 163 159
Equity Capital 10 13 14 14 17 18 20 22 22 22 22 22 22

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 (S) Mar 2026 (S)
Cash from Operating Activity + -45 -15 -11 -6 4 -36 -15 -17 -25 2 -8 -2
Cash from Investing Activity + -3 -4 -5 -3 -4 -10 -23 -23 -13 -8 -5 -4
Cash from Financing Activity + 54 13 16 9 17 29 38 40 37 6 13 6
Net Cash Flow 6 -6 0 0 17 -17 1 -1 0 0 0 0
Free Cash Flow -48 -23 -17 -9 -1 -45 -40 -41 -36 -5 -11 -5
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 924 123 140 83 -40 191 83 51 157 -27 52 35

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 72.74% → 72.74%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 26.77% 26.75% 26.75% 26.76% 26.76% 26.75% 26.76% 26.76% 26.76% 26.77% 26.76% 26.75%
Promoters 72.74% 72.74% 72.74% 72.74% 72.74% 72.74% 72.74% 72.74% 72.74% 72.74% 72.74% 72.74%
FII 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5% 0.5%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Krebs Biochemicals & Ind (this stock) — — — —
Sun Pharmaceutical Ind L 451,075 36.7 5.05 16.0%
Divi S Laboratories Ltd 294,139 86.1 16.34 16.5%
Torrent Pharmaceuticals L 177,632 81.8 9.67 27.4%
Apollo Hospitals Enter. L 125,893 55.6 11.86 21.5%
Laurus Labs Limited 125,380 93.6 20.73 18.3%
Zydus Lifesciences Ltd 118,693 26.2 4.27 21.2%

Which Mutual Funds Hold Krebs Biochemicals & Ind?

Frequently Asked Questions about Krebs Biochemicals & Ind

Community Sentiment

What are other investors saying about Krebs Biochemicals & Ind?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.